Novo Nordisk US Legal Case: Why the CagriSema Shareholder Lawsuit Will Continue
Novo Nordisk must continue defending part of a US shareholder lawsuit alleging that investors were misled about the clinical trial for CagriSema, the company’s experimental obesity and diabetes treatment. On…